Frontage Laboratories, Inc’s Post

See you there, if you want to learn more about the myeloid cell "mess" and how to target it in fibrotic diseases.

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/3XVKzx4 #CAGT #drugdevelopment #clinicalstudies

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/3WFCH26 #CAGT #drugdevelopment #clinicalstudies

To date, we have published two short videos exploring our new and exciting partnership with US-based company, Ichor Life Sciences, Inc. A collaboration built upon the shared values of spirit, culture and integrity, the synergy between our two businesses is undoubtedly clear. In this new feature, our Founder and Director, A/Prof Tina Soulis ALITHIA LIFE SCIENCES (CRO), and President of Clinical Trial Services at Ichor Clinical, Lisa Sonneborn, MA, LMHC, explain why the Alithia x Ichor service model sets us apart from others in the industry. #lifesciences #lifesciencesindustry #clinicaltrials #clinicalresearch #contractresearchorganization #servicemodel #collaboration #partnership #australia #unitedstates

📢 Exciting news from our CEO, Simon Chandler! In a recent blog by RNID in partnership with BIA, Simon delves into the dynamic landscape of commercialising hearing research.   The journey to developing hearing therapies is filled with potential, driven by advanced insights into hearing biology, partnerships with clinical communities, and a supportive regulatory environment. However, the path is not without its challenges. Transforming scientific discoveries into clinical therapeutics demands innovative solutions.   At Rinri Therapeutics, we are at the forefront of addressing these obstacles. By pioneering new delivery methods, designing novel clinical trial frameworks, and enhancing manufacturing processes, we aim to broaden the impact of our ground-breaking treatments. Our flagship product, Rincell-1, exemplifies our swift preclinical progress, and we are on track to begin clinical trials in the UK within the next 18 months. Our goal: to be the first to offer a comprehensive therapeutic solution for the hearing loss community.   This is a pivotal moment to tackle hearing loss. We urge researchers, pharmaceutical firms, and investors to join us in advancing innovative therapeutics that promise to transform the lives of millions.   🔗 Read the latest blog here: https://lnkd.in/eWf7jmid #HearingLoss #RegenerativeMedicine #Innovation #Healthcare #Celltherapy #cellandgenetherapy #atmps #atmp #yorkshirebusiness #ukbusiness

Lipum to participate in the following upcoming events and meetings: NLSDays | 18-19 September | Malmö BioEurope | 4-6 November | Stockholm Redeye Autoinflammatory day | 20 November | Stockholm BioStockSummit | 20-21 November| Lund "These meetings provide a good opportunity for us to present and discuss our progress and results from our first clinical phase 1 study, to share our ongoing plans as well as presenting key milestones and triggers with investors and partners" says CEO Ola Sandborgh. #lipum #investorrelations #lifescience

We are excited to share with you our ambitions for the next 4 years. Building on the achievements of the past strategic plan, and the decade since ECRIN has achieved its ERIC status, the new strategic plan is marks a consolidation phase for ECRIN. To meet our objectives we have built the strategic plan around five overarching goals to drive ECRIN’s activity for 2024-2027: 1) Ensure scientific excellence and public health relevance 2) Cultivate a thriving and empowered ECRIN community 3) Forging the path for future ECRIN activities 4) Consolidate and promote our visibility and awareness 5) Sustain engagement with the research infrastructure ecosystem Delve into our strategic plan today: https://lnkd.in/eAmEEcT3 CZECRIN, Infrastructure F-CRIN, GreCRIN, HNHRA, HRB National Clinical Trials Office (NCTO), ItaCRIN, KKSN, NorCRIN, PCTN, PtCRIN Portuguese Clinical Research Infrastructure Network, Spanish Clinical Research Network (SCReN), SLOVACRIN, Swiss Clinical Trial Organisation, ERIC Forum

JAFRON HA SERIES What it is - What it is not. This series of articles are our experiences with the Jafron HA series, especially in clinics in Turkey and in our direct relationships with Jafron. - Examining all aspects of the products in this article series - Known and unknown details of product differences - Our clinical development processes and market reflections -CE; MDR and prospectus details - Our field sales strategies and competitor analysis - Third world countries and European perspective: Where is Türkiye - Overview of clinical studies. Why do we stay away from prospective studies? - Many topics such as our 10-year adventure from amateur to professional will be discussed in detail. The purpose of this series of articles is to share our experiences by covering all the processes of an evolving treatment. In this sense, we think that "What it is - What it is not" is the most appropriate title for us. We start on Friday, March 22nd. #jafron #cytokine #hemoperfusion #hemoadsorption #sepsis #cytosorb #oxiris #cpfa #seraph100 #efferon

PCM Trials acquired EmVenio Research, becoming the largest independent decentralized clinical trials site network and the most experienced provider of local clinical trial access globally. With the addition of EmVenio’s capabilities, PCM Trials now offers the most patient-centric model available for hybrid and decentralized clinical trials.  #decentralizedclinicaltrials